Before patients with cancer begin treatment with intravenous fluorouracil and related drugs, they should be tested for lack of the enzyme dihydropyrimidine dehydrogenase (DPD), says an EU panel.

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Patients with cancer who are to receive fluorouracil (multiple brands) given by injection or infusion should be tested for lack of an enzyme called dihydropyrimidine dehydrogenase (DPD) prior to the ...

Reply to: “Give Patients the Choice to Test for DPD Deficiency Before Fluoropyrimidine Chemotherapy,” “Large-Scale DPD Testing Should Be More Than an Option,” and “A Big Problem With a Feasible ...